Effect of thyme-ivy syrup on antiviral immune response in patients with mild COVID-19: a prospective, open-label, randomized pilot study
The exploratory BroVID study identified treatment differences in immune response mediators with moderate to large effect sizes for thyme-ivy syrup vs. control in patients with mild COVID-19; these differences require validation in a larger confirmatory study. The findings may be subject to bias due to imbalanced baseline characteristics, the inter- and intra-individual heterogeneity of inflammatory markers, and the small sample size.
Authors
- Frank Behrens (ORCID: https://orcid.org/0000-0001-8750-7186)
- Ann Christina Foldenauer (ORCID: https://orcid.org/0000-0003-2049-3204)
- Maximilian Klippstein
- Tanja Roßmanith (ORCID: https://orcid.org/0000-0001-8467-2522)
- Stephanie Dauth (ORCID: https://orcid.org/0000-0002-2752-3739)
- Gerd Geißlinger (ORCID: https://orcid.org/0000-0003-0552-7488)
- Susanne Schiffmann (ORCID: https://orcid.org/0000-0001-5035-2504)
- S.M.G. Schäfer (ORCID: https://orcid.org/0000-0003-4429-1842)
- Maria J. G. T. Vehreschild (ORCID: https://orcid.org/0000-0002-7282-2842)
- Michaela Koehm
- Christin Jonetzko
Institutions
- Goethe University Frankfurt (DE)
- Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fmed.2025.1672794
- Primary Topic
- Essential Oils and Antimicrobial Activity
- Type
- article
- Field-Weighted Citation Impact
- 0.00